

Completion of Phase 2a clinical trial in Rheumatoid Arthritis

Release dated 9 May 2006

CBio has today formally completed the first Phase 2a trial in Rheumatoid Arthritis in 23 patients.

The results in this exploratory study met all expectations and confirm the high potential of CBio's product XToll™ (Chaperonin 10) in treating Rheumatoid Arthritis and potentially other autoimmune and chronic inflammatory diseases.

XToll™ has been shown to work by a mode of action different to the existing anti-TNF therapies and with a good safety profile.

Results of the clinical trial and mode of action studies are being submitted to international peer reviewed journals for publication.

The clinical trial was carried out in Melbourne (Dr Stephen Hall of Emeritus Research), Perth (Dr Andrew Taylor of Goatcher Clinical Research Unit) and Maroochydore (Dr Peter Nash, Rheumatology Research Unit, Coast Joint Care).

The Principal Investigator, Dr Stephen Hall stated "this novel compound showed great promise with minimal side-effects in this small, preliminary study".

CBio will now progress the further commercial development of XToll™.

For further information please contact:

Dr Dennis Feeney
Chief Scientific Officer
Ph. 07 38414844
Fax 07 38418189
Mobile 0412617311

Dr Wolf Hanisch
Chief Executive Officer
Ph. 07 38414844
Fax 07 38418189
Mobile 0412339460

Contact:

85 Brandl Street
Brisbane Technology
Park
Eight Mile Plains
Qld 4113 Australia

PO Box 8104
Sunnybank Plaza
Sunnybank
Qld 4109 Australia

Ph: 61 7 3841 4844
Fax: 61 7 3841 8189

www.cbio.com.au

ABN: 76 094 730 417
ACN: 094 730 417